Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination
Sponsor: Marc de Perrot • ClinicalTrials.gov ID: NCT04782752
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This is a prospective phase I study to determine the safety and feasibility of non-ablative oligofractionated radiation therapy (NORT) before lung transplantation for patients with underlying pulmonary malignancy. We hypothesize that heterogeneous dose distributions could generate a vaccination effect against the tumor by creating anti-tumoral immune response in the body and these patients may be immunized against their tumor which could reduce the risk of cancer recurrence after transplantation despite the anti-rejection medications required for the transplantation.
Interventions
-
Radiation: Varying Doses of RT
(Radiation)
3+3 radiation dose escalation model to see the maximum tolerated dose
Eligibility criteria
Conditions
Locations
- Toronto General Hospital, University Health Network — Toronto, Ontario, Canada
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record